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Epidemiological studies suggest that being obese in midlife is a risk factor for cognitive decline and dementia in later life.
Hyperinsulinemia is one of the most frequent endocrine features in overweight people which results in insulin desensitization.
Thus, chronically high insulin levels have been identiﬁed as risk factor for dementia. Accordingly, chronically high insulin levels
might be harmful for brain function. Furthermore, insulin and IGF-1-induced signaling is reduced in the brains of patients
suﬀering from Alzheimer’s disease (AD). Interestingly, studies in rodents suggest that reduced insulin receptor (IR) and insulin-
like growth factor-1 receptor (IGF-1R) signaling decrease AD pathology, that is, β-amyloid toxicity. Data obtained in C. elegans
indicate that the beneﬁcial eﬀect mediated via reduced IR/IGF-1R signaling might partially be induced via the forkhead-box O
transcription factors (FoxO). In the mammalian brain, there are FoxO1, FoxO3a, and FoxO6 expressed. Surprisingly, high-fat diet
speciﬁcally reduces the expression of FoxO3a and FoxO6 suggesting that IR/IGF-1 → FoxO-mediated transcription is involved in
the pathogenesis of obesity-associated cognitive impairment. Therefore, the function of FoxO1 and FoxO3a has been investigated
in animal models of Alzheimer’s disease in detail. The current paper focuses on the role of IR/IGF-1 signaling and IR/IGF-1 →
FoxO-mediated transcription for the pathogenesis of obesity-associated dementia.
1.Introduction
Obesity is characterized by a body mass index (BMI) of over
30kg/m2. The prevalence of obesity will rise to approximate-
ly 700 million people worldwide in 2015 [1]. Furthermore,
midlife overweight and obesity might increase the risk for
dementia during aging [2–4]. Hence, the role of obesity or
overweight status in the development of cognitive decline or
dementia is a major health concern and possibly associated
with enormous health care costs. Prospective investigations
on the role of BMI for the development of dementia did
not provide a conclusive picture, yet. Some studies report
no association or even decreased BMI to be associated
with dementia or Alzheimer’s disease [5, 6], and others
suggested higher BMI to be a risk factor for dementia [7]o r
that overweight in middle age is associated with dementia
decades later [8, 9]. It seems to be diﬃcult to estimate
the exact role of obesity itself for the initiation or progress
of cognitive impairment. Furthermore, obesity is associated
with a variety of cardiovascular risk factors inﬂuencing
long-term cognitive performance. Moreover, lower cognitive
abilities are a risk factor for obesity, but on the other hand,
dementia in later life might be associated with lower BMI.
Thus, it might well be that obesity in younger or midlife is
a risk factor for dementia, and dementia is causing weight
loss and cachexia on the long run. Taken together, cognitive
performancemightinﬂuencethepathogenesisofobesityand
being overweight the development of cognitive impairment,2 Current Gerontology and Geriatrics Research
dementia, and neurodegeneration. This interrelationship
between body weight and cognitive function implicates the
need for lifetime studies and standardized tests to identify
cause or consequences of obesity-associated dementia. The
complex interplay might at least partially explain the dif-
ferent results obtained by diﬀerent studies. However, there
is growing evidence that disturbed metabolic signals in
obesity or type 2 diabetes feedback to the central nervous
system (CNS) inﬂuencing brain function and possibly the
pathogenesis of dementia or cognitive decline.
Recently, insulin and insulin-like growth factors (IGFs)
have been suggested as important modiﬁers for the patho-
genesis of neurodegenerative diseases, providing a link
between obesity, type 2 diabetes (T2D), and cognitive
impairment or even the pathogenesis of Alzheimer’s disease.
An important key mediator of insulin and IGF-1-mediated
eﬀects are the forkhead box O (FoxO) transcription factors.
These transcription factors are involved in the neuronal
proliferation, diﬀerentiation, stress response, and β amyloid
detoxiﬁcation.
The current review discusses the role of insulin and
insulin-like growth factor-1/FoxO-mediated transcription
for the pathogenesis of obesity-associated dementia from
model organisms to humans.
2. ObesityandDementia
As mentioned above, there might be a complex interplay
betweencognitionandmetabolicsignalsbetweentheperiph-
eral blood and the CNS. Obesity is associated with a whole
variety of metabolic signals feeding back to the brain for
example, leptin, insulin, or diﬀerent cytokines. Furthermore,
timing of “metabolic injuries” might be crucial for cognitive
function during later life. Thus, it is not surprising that
epidemiological studies show diﬀerent results depending
on the study collective, duration of study, phase of life
investigated, and comorbidities (e.g., T2D).
In detail, Stewart and coworkers showed that in a
prospective, population-based study of Japanese American
menovera32-yearperiod that(dementia-associated)weight
loss begins before the onset of the clinical syndrome and
accelerates by the time of diagnosis [6]. Thus, weight loss
is part of the clinical presentation of patients suﬀering
from dementia, for example, AD. Another study showed
a link between an increased BMI and the risk to develop
Alzheimer’s dementia in elderly people 10 years before
the onset of symptoms, suggesting that the period in
life of being overweight might be an important issue
[7].
Interestingly, there are several studies supporting the
hypothesis that obesity in midlife plays a role in the
development of dementia in later life [8, 9].
The possible role of the surveillance periods of exposure
to overweight for cognitive function during life has recently
been reviewed by Elias and coworkers [10]. In addition, the
Swedish Adoption/Twin Study of Aging (SATSA) focused on
the relation of BMI and cognitive decline over a time period
of over 40 years. This study showed an association of higher
BMI in midlife and cognitive decline in males and females
[11]. Furthermore, the Finnish Twin Cohort Study revealed
that the BMI in midlife as well as cardiovascular risk factors
are associated with reduced cognitive abilities during aging
[12].
Taken together, low BMI and weight loss seem to be the
ﬁrst clinical manifestation of neurodegeneration even before
the onset of perceivable cognitive impairment. However,
even still heterogeneous, recent data suggest that certain
periods of exposure to obesity during life might be crucial
for cognitive function during aging.
3. Hyperinsulinemiaand Dementia
Chronic hyperglycemia impairs cerebral blood ﬂow [13]a s
well as central glucose utilization [14]. Interestingly, central
insulin ameliorates cognitive function, and acute central
insulin administration leads to improved spatial memory
in mice [14]. Accordingly, intranasal application leads to
increased verbal memory in humans [15]. In the Nurses’
HealthStudy(NHS),nondiabeticwomenwithhigherfasting
insulin levels tended to have lower performance on global
and verbal cognition. Furthermore, higher levels of fasting
insulin were associated with faster rates of cognitive decline
[16]. However, insulin levels were relatively low in this
study indicating a potential role of even modestly elevated
insulin concentrations. In the Physicians’ Health Study,
higher late-life fasting insulin levels among nondiabetic
men were associated with a greater subsequent decline
in general cognition [17]. Taken together, insulin in the
short run might improve cognition, but chronically ele-
vated insulin levels are associated with faster cognitive
decline during aging. Thus, alterations of insulin levels
and insulin-mediated signals/transcription might be an
interestingcandidatetoexplaintheassociationofobesityand
dementia.
4. Insulin/Insulin-LikeGrowth
Factor-1 Signaling
Insulin receptors (IRs) are present in the so-called classic
insulin responsive tissues such as muscle, fat, or liver
and nonclassic tissues such as brain, endothelial cells, or
gonadal cells. In 1978, Havrankova et al. demonstrated
for the ﬁrst time the localization of IRs in the CNS,
an organ classically considered as an insulin-insensitive
tissue. Moreover, insulin enters the CNS across the blood
brain barrier through an active transport mechanism [18–
21]. The localization of insulin receptors in the CNS was
assessed by various techniques, including in vitro binding
studies [22], in vivo and in vitro autoradiography and
computerized densitometry [21–25] and immunocytochem-
istry [26]. According to these studies, insulin receptors are
widely distributed in the brain with highest concentrations
in the olfactory bulb, hypothalamus, cerebral cortex, and
hippocampus.
The insulin and IGF-1 receptor (IR/IGF-1R) are tyrosine
kinases which consist of a membrane bound domain withCurrent Gerontology and Geriatrics Research 3
tyrosine kinase activity. This tyrosine kinase phosphorylates
tyrosine residues of downstream signaling proteins like
insulin receptor substrates (IRSs). The IR and IGF-1R
have a heterotetrameric structure with extracellular localized
α-subunits and membrane bound β-subunits. These β-
subunits contain ATP-binding motifs, autophosphorylation
sites, and tyrosine protein kinase activity activated after
binding of insulin or IGF-1 to the receptor [27–29]. Binding
oftheligandresultsinconformationalchangeofthereceptor
andinducesautophosphorylationfollowedbyrecruitmentof
IRS proteins which get thereby tyrosine phosphorylated. The
IRS protein family consists of four members, IRS-1 to 4 [30–
32]. These IRS proteins consist of an pleckstrin homology
(PH) domain located at the N-terminus, a phosphotyrosine-
binding (PTB)domain and aC-terminus with multiple tyro-
sine phosphorylation sites. These phosphotyrosine motifs
of the IRS proteins are binding sites for Src homology
(SH)2 domain-containing proteins [33]. Furthermore, the
PH domain interacts with phosphoinositides, while the PTB
domain binds to phosphotyrosine residues of, for example,
the IR and IGF-1R [34–36]. Insulin induces tyrosine and
serine phosphorylation of IRS-1 which leads to positive or
negative regulation of IRS-1 and the downstream signaling
pathway [37–39]. The mammalian phosphatidylinositide
(PI) 3-kinase family consists of classes I to III, and class I
is subdivided into classes Ia and Ib [40]. PI3K, a class Ia
kinase, induces phosphorylation of the 3  hydroxyl position
of phosphatidyl-myo-inositol lipids [41]. The PI3K shows
a heterodimeric structure with a catalytic 110kDa subunit
which is noncovalently bound to a 50-, 55-, or 85kDa
regulatorysubunit.AfterbindingandactivationofIRStothe
IR or IGF-1R, the PI3K is recruited to the membrane using
the p85 regulatory subunit. Additionally, the growth factor
receptor binding protein (GRB)-2 and the SH2-phosphatase
(SHP) 2 are recruited after activation of the IR/IGF-1R
signaling pathway. Activation of the PI3K leads to phos-
phorylation of phosphatidylinositide diphosphate (PI4,5P) to
generate phosphatidylinositide triphosphate (PI3,4,5P). The
phosphorylation of PI4,5P is reduced via PTEN (phosphatase
a n dt e n s i nh o m o l o gd e l e t e do nc h r o m o s o m et e n )a c t i o n .
Following this step, the downstream signaling proteins
like phosphoinositide-dependent protein kinase (PDK) and
protein kinase B (PKB, AKT) are activated. PDK has two
isoforms, PDK-1 and PDK-2. PDK-1 phosphorylates AKT
at Thr308 [42–44]. AKT is a serine/threonine kinase with a
sizeof57kDa.AKToccursinthreeisoforms,AKT-1toAKT-
3. The structure of AKT consists of a PH domain, a kinase
domain, and an N- and C-terminal regulatory subunit [45].
In addition to the PI3K pathway, insulin and IGF-1 activate
the MAP kinase (MAPK, mitogen-activated protein kinase)
signaling cascade (Figure 1)[ 36, 46, 47].
5. Forkhead-Box O TranscriptionFactors
FoxOs diﬀer in their expression pattern. FoxO1 and FoxO3a
areubiquitouslyexpressed.Incontrast,FoxO6onlyoccursin
the brain, whereas FoxO4 has not been found in the brain so
far[48,49].FoxO1ispredominantlyexpressedinthedentate
gyrus, striatum, and ventral hippocampus, while FoxO3a
mainly occurs in the cerebellum, cortex, and hippocampus.
FoxO6isfoundinthehippocampus,amygdala,andcingulate
cortex of the adult murine brain [50, 51].
Activated AKT phosphorylates forkhead-box O tran-
scription factors which leads to binding of 14-3-3 inducing
their nuclear exclusion. This inactivates FoxO-mediated
transcription which regulates apoptosis, growth, metabo-
lism, and cellular diﬀerentiation under active conditions
[52].
The mammalian FoxO transcription factor family con-
tains 4 proteins: FoxO1, FoxO3a, FoxO4, and FoxO6. These
proteins share a conserved DNA binding domain, the
forkhead domain (FKHR) binding to a consensus FoxO-
recognized element (FRE) sequence of the target gene
(G/C)(T/A)AA(C/T)AA [48, 53, 54]. Target genes of FoxO-
mediated transcription are, for example, Fas ligand (FasL),
p27KIP1 [55, 56], and manganese superoxide dismutase
(MnSOD) [57] (Figures 2 and 3).
FoxO-mediated transcription is regulated via posttrans-
lational modiﬁcations. One major modiﬁcation is the phos-
phorylation of diﬀerent sites within FoxOs. Upon activation,
AKT phosphorylates FoxO1 at Thr24, Ser256, and Ser319
[53, 59–62]. FoxO3a becomes phosphorylated at Thr32,
Ser253, and Ser315 via AKT [63]. Furthermore, FoxOs are
phosphorylated via diﬀerent kinases depending on the stim-
ulus (review in [64]). Other posttranslational modiﬁcations
are ubiquitination. FoxO1 is ubiquitinated via Skp2, the
substrate-bindingcomponentoftheSkp1/culin1/F-boxpro-
tein (SCFSkp2) E3 ligase complex. This ubiquitination occurs
after phosphorylation of FoxO1 at Ser256 via AKT [65–68].
FoxO1 and FoxO3a are polyubiquitinated, while FoxO4 is
monoubiquitinatedfordegradation[69].Additionally,FoxO
transcriptionfactorsaremethylated,forexample,FoxO1gets
methylated at Arg248 and Arg250. These sites are located
in the AKT phosphorylation motif. This methylation is
promoted by the protein arginine N-terminal methyltrans-
ferase 1 (PRMT1) protecting FoxO1 from phosphorylation
via AKT, translocation out of the nucleus, and degradation
[70]. Furthermore, FoxOs are acetylated via CBP and p300
withtheirinteractingproteinslikeCBP-andp300-associated
factor (PCAF) [71]. The acetylation of FoxOs decreases
DNA binding and promotes phosphorylation of FoxO via
AKT which inactivates FoxOs [72, 73]. Deacetylation of
FoxOs is induced by silent information regulator 1 (SIRT1),
a nicotinamide-adenine-dinucleotide- (NAD-) dependent
histone deacetylase [74, 75].
FoxO-mediated transcription is involved in several pro-
cesses. One of them is controlling cell cycle arrest via regu-
lation of transcription of, for example, the cyclin-dependent
kinase inhibitor p27 (review in [76]). Under conditions of
growth factor deprivation, the IR/IGF-1R signaling pathway
isinactive,andFoxOsareactiveinducing cellcyclearrestand
quiescence to promote survival [57]. Additionally, FoxOs are
involved in oxidative stress response (Figures 2 and 3). To
counteract reactive oxygen species (ROS) produced during
oxidative stress, FoxOs increase expression of antioxidant
e n z y m e sl i k eM n S O D[ 57].4 Current Gerontology and Geriatrics Research
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Figure 1: Central IR/IGF-1 signaling. Binding of insulin and IGF-1 to their receptors leads to autophosphorylation of the β-subunits of
the IR or IGF-1R, recruitment of IRS-1/-2, and subsequently activation of mainly two pathways the PI3 kinase pathway and the MAP
kinase cascade. The PI3 kinase pathway activates Akt which inhibits GSK-3β. Akt-mediated FoxO1 phosphorylation results in binding of the
regulatoryprotein14-3-3andnuclear exclusionofFoxO1.Abbreviations:IR,insulinreceptor;IGF-1R,insulin-likegrowthfactor-1receptor;
IRS,insulinreceptorsubstrate;PI3K,PI3kinase;FoxO1,forkhead-boxproteinO1;PDK,phosphatidylinositide-dependentkinase;p110/p85,
catalytic/regulatory subunit of PI3K; PI3,4P, phosphatidylinositide 3,4-diphosphate; PI3,4,5P, phosphatidylinositide 3,4,5-triphosphate; PTEN,
phosphatase and tensin homolog deleted on chromosome ten; 14-3-3, regulatory protein 14-3-3; PP2A, protein phosphatase 2A.
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Figure 2: Function and targets genes of FoxO transcription
factors. Abbreviations: IR, insulin receptor; PGC1, peroxisome-
proliferative-activated receptor-γ (PPARγ) coactivator 1; BIM,
Bcl2-interacting mediator of cell death; p21, cyclin-dependent
kinase inhibitor 1 (review in [58]).
6. Expressionof FoxO during Aging
andHigh-FatDiet
FoxO transcription factors show a distinct temporal and
spatial expression pattern at least in the murine brain.
TheanalysisofFoxOexpressionindiﬀerentregionsofmouse
brain up to 100 weeks of age revealed that FoxO1 is predom-
inantly expressed in the hippocampus compared to overall
expression in the whole brain, whereas FoxO3a showed its
highest expression in the cerebellum [51]. Furthermore,
expression of FoxOs in C57BL/6 mice strongly respond to
a high-fat diet (HFD) at least if fed over 46 weeks. Western
blot analysis of cortex lysates of these HFD mice revealed
increased phosphorylation of AKT at Ser473 compared to
mice on STD (standard diet) indicating increased IR/IGF-
1 signaling in these mice. Surprisingly, FoxO1 mRNA levels
were slightly increased in the CNS of HFD mice, wheras
FoxO3a mRNA levels were signiﬁcantly decreased in the
cerebellum, frontal, parietal, and occipital cortex. Even more
strikingly, the expression of FoxO6 was upto 80% decreased
in all analyzed brain regions [51]. In line with these in vivo
data, SH-SY5Y human neuroblastoma cells stably overex-
pressing IRS-2 showed increased phosphorylation of AKT
at Ser473 and analysis of mRNA levels of FoxO3a revealed
signiﬁcantly reduced expression as observed in the CNS of
mice fed a HFD indicating that chronically elevated IR/IGF-
1R signaling in neurons leads to downregulation of FoxO3a
in vivo and in vitro [51]. The exact molecular mechanism
how IR/IGF-1R signaling cascade regulates expression of
the diﬀerent FoxOs is still under investigation. However,
data obtained in cell lines might not exactly reﬂect the
in vivo situation. Thus, hyperinsulinemia in mice fed a
HFD over a long period induces decreased expression of
FoxO transcription factors, for example, FoxO3a and FoxO6,
suggesting that disturbance of FoxO-mediated transcriptionCurrent Gerontology and Geriatrics Research 5
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Figure 3: FoxO phosphorylation sites regulated via diﬀerent
kinases. Abbreviations: PKB, protein kinase B/Akt; SGK, serum-
and glucocorticoid-induced protein kinase; cGK, cGMP-dependent
protein kinase type 1; MST1, mammalian sterile 20-like 1 kinase;
CDK 2, cyclin-dependent kinase 2; CK1, casein kinase 1; DYRK,
dual speciﬁcity tyrosine-phosphorylation-regulated kinase; JNK, c-
Jun N-terminal kinase; IKK, IκB-kinase, NLS, nuclear localization
signal; NES, nuclear export signal; FKH, forkhead domain; TA,
transactivation domain.
downstream of the insulin signaling pathway might be
involved in the pathogenesis of obesity-associated cogni-
tive dysfunction. The hypothesis is supported by animal
experiments indicating a role for IRS-2-mediated signals for
memory formation [77]. Mice harboring a brain-speciﬁc
deletion of IRS-2 showed enhanced spatial working memory.
Taken into account that decrease in IRS-2 signaling induces
FoxO-mediatedtranscription,theassumptionthatdecreased
FoxO expression observed in HFD mice is involved in
the pathogenesis of obesity-associated cognitive impairment
seems reasonable or even likely. There is growing evidence
that at least in AD IR/IGF-1 signaling is disturbed. Thus,
IR/IGF-1-regulated transcription might be a part of the
pathogenesis of at least AD. However, it is still unclear
whether the changes in neuronal IR/IGF-1 signaling is cause
or counterregulation in response to neurodegeneration.
7. Alzheimer’s Disease
Alzheimer’s disease is a chronic and progressive neurodegen-
erative disease. It is the most common form of dementia
leading to cognitive decline and death [78, 79]. Character-
istics of AD are neuroﬁbrillary tangles (NTFs) and β amyloid
plaques. NTFs consist of hyperphosphorylated (abnormal
high phosphorylation) tau proteins, and β amyloid plaques
contain aggregated amyloid-β (Aβ)p e p t i d e s[ 80, 81]. It is
hypothesizedthattheaccumulationofAβistheleadingcause
for neurodegeneration in the progression of AD [80].
Several clinical studies showed that the IR/IGF-1R sig-
naling is impaired in the central nervous system (CNS) of
patients suﬀering from AD [82–84]. The expression of the
IR and the IGF-1R was reduced in brains of AD patients
[84, 85], whereas increased IGF-1 serum levels were detected
[85,86].Additionally, the expression levelsofIRS-1andIRS-
2 were reduced, and the inhibitory serine phosphorylation
of IRS-1 at Ser312 and Ser616 was increased in AD brains.
These ﬁndings indicate AD to be a brain type diabetes [87].
Tau predominantly occurs in the axons of neurons [88]
and is less present in dendrites [89]. Tau might be involved
in stabilization of microtubules and regulation of axonal
transport [90]. It contains an N-terminal projection domain
and a short tail sequence. The C-terminal domain consists
of microtubule-binding (MTB) repeats. Tau gets phospho-
rylated at diﬀerent sites by a variety of kinases. GSK3β
predominantly phosphorylates tau and is regulated via the
IR/IGF-1Rsignalingpathway.ActivatedAKTphosphorylates
Ser9 of GSK3β to inhibit its action. An important phos-
phatase of tau is PP2A (protein posphatase 2A) [91]. This
phosphatase is also regulated via the IR/IGF-1R signaling
cascade indicating that insulin and IGF-1 action promotes
both phosphorylation and dephosphorylation leading to
equilibrium of tau phosphorylation at least under certain
circumstances [91, 92].
Aβ peptides, the main component of amyloid plaques,
are produced via proteolytic cleavage of the amyloid pre-
cursor protein (APP). APP belongs to the type-1 integral
membrane protein family [93–96]. The APP gene is local-
ized on chromosome 21, therefore patients suﬀering from
trisomy21presentanincreasedriskforAD.Hence,increased
APP expression results in Alzheimer-like pathology [97, 98].
Furthermore, mutations in the APP gene itself like the
Swedish mutation (APPsw) or mutations in presenilin 1 and
presenilin2whichareinvolvedinproteolyticcleavageofAPP
lead to familial early-onset AD (FAD) [99–107].
Diﬀerent APP splicing variants with distinct molecular
weight are generated in vivo. APP containing 751 or 770
amino acids (APP751 and APP770) is expressed in non-
neuronal tissue, while APP695 is predominantly found in
neurons [108]. The function of APP and APP-like protein
(APLP) is not well understood. These proteins might be
involved in apoptosis, axonal transport, and cell adhesion.
APP and APLP are expressed in nearly all vertebrates and
invertebrates [109–111]. The structure of APP consists of an
N-terminal extracellular and a C-terminal domain located in
the cytoplasm. Proteolytic cleavage of APP is promoted via
the β-secretase BACE-1 (β-site APP cleaving enzyme) which
leads to the “amyloidogenic pathway” of APP cleavage. APP
is cleaved at Asp+1 of the N-terminus via BACE-1 which
leads to the generation of soluble APPsβ and the C-terminal
fragment C99 (Figure 4). C99 is cleaved via the γ-secretase,6 Current Gerontology and Geriatrics Research
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a complex formed by presenilin, nicastrin, Aph-1, and Pen-
2. This cleavage results in the production of Aβ (4kDa) and
the APP intracellular domain (AICD) with a size of 6kDa.
Aβ-peptides are mainly found in two variants which are
distinguishable because of their size. Aβ40 ends at residue
40 and Aβ42 ends at residue 42. Predominantly, the Aβ42
is susceptible to aggregate and forms neurotoxic oligomers.
In contrast, the “nonamyloidogenic pathway” starts with
cleavage of APP via the α-secretase ADAM10 (a disintegrin
and metalloproteinase-like 10) or TACE (tumor necrosis
factor-alpha convertase) which leads to the generation of
the soluble APPsα and the C-terminal fragment C83. The
decision whether the amyloidogenic or nonamyloidogenic
cleavage pathway is induced depends on the competition
of the α-a n dβ-secretase [107, 110]. Up to 90% of all
Aβ-peptides in brains of healthy people are Aβ40, whereas
Aβ42 is less produced with about 5 to 10% [112]. The
accumulation of Aβ42 is a major step in the formation
of Aβ oligomers amyloid plaques [113]. Aβ oligomers
show an increased cytotoxic eﬀect compared to mature Aβ
ﬁbrils [114–116]. Aβ-derived diﬀusible ligands (ADDLs) are
aggregates with a size of about 17 to 42kDa and present
no ﬁbrillar structure but are neurotoxic [117–119], and the
concentrations of ADDLs correlate to cognitive impairment
in AD [120].
The exact mechanism how Aβ facilitates its neurotoxic
eﬀect is not completely understood yet, but toxicity might
be induced via generation of ion channels, membrane
disruption, oxidative stress, induction of apoptosis, and
inﬂammation [121–124].
8.Insulin/IGF-1Signalingand
FoxO-MediatedTranscriptioninthe
Pathogenesis of Alzheimer’s Disease
In cultured human neurons, Hong et al. [125] showed
that glycogen synthase kinase-3 (GSK-3) phosphorylates the
neuronal protein tau. Hyperphosphorylated tau is the major
component of paired helical ﬁlaments in neuroﬁbrillary
lesions associated with Alzheimer’s disease. Hyperphos-
phorylation reduces the aﬃnity of tau for microtubules
and is thought to be a critical event in the pathogenesis
of tauopathies. Insulin and IGF-1 have been shown to
reduce the phosphorylation of tau protein by inhibiting
activity of GSK-3. In vivo IRS-2-deﬁcient mice, a model
of insulin resistance and type 2 diabetes, displayed tau-
hyperphosphorylation and developed intracellular deposits
of hyperphosphorylated tau during aging [126] suggesting
a critical role for IR/IGF-1 signaling in regulation of tau
phosphorylation in vivo.
Previous studies suggest that insulin and IGF-1 sup-
port neuronal survival in vitro. In particular, insulin/IGF-
1 strongly activates AKT/PKB to promote BAD phosphory-
lation and its association with 14-3-3, which releases Bcl-2
to inhibit apoptosis [127]. Furthermore, IR/IGF-1-receptor
signal transduction regulates the processing and secretion
of APP [128, 129], and Xie et al. [129] have demonstrated
that β-amyloid peptides compete for insulin’s binding to
the IR. As mentioned above, IR/IGF-1R is reduced in AD
brains strongly suggesting a role for IR/IGF-1 signaling
in the pathogenesis of AD. This is supported by several
animal models. For example, IGF-1-deﬁcient mice presented
increased tau phosphorylation at Ser396 and Ser202 [130].
The brain-speciﬁc knockout of the IR (NIRKO) showed
highly phosphorylated tau at Thr231 [131]. IRS-2-deﬁcient
mice displayed “hyperphosphorylation” at Ser202 [126].
Thus, genetically induced IGF-1 or insulin resistance in
mice induces tau hyperphosphorylation, indicating that at
least the tau part of AD pathology is enhanced by insulin
resistance in vivo.
In contrast, animal experiments suggest a diﬀerent role
of IR/IGF-1 signaling for the β amyloid pathology in AD.
Tg2576 mice express the human-derived APP harboring
the Swedish mutation (APPsw) inducing increased Aβ
burden and AD-like pathology [107, 132–135]. Mice withCurrent Gerontology and Geriatrics Research 7
a neuron-speciﬁc IGF-1R deletion (nIGF-1R−/−)o rI R S -
2 knockout (IRS-2−/−) crossed with Tg2576 mice were
protected from premature death and showed decreased Aβ
accumulation [136]. Interestingly, neuron-speciﬁc deletion
of the IR (nIR−/−) in a Tg2576 background showed decrease
in Aβ burden but displayed no survival beneﬁt compared to
Tg2576 mice [137].
A rather interesting study investigated the role of partial
IGF-1 resistance in an AD mouse model overexpressing
APPsw and the human presenilin-1 ΔE9 variant under
control of the prion promoter [138] .T h e s eA Dm i c ew e r e
crossed with mice heterozygote for the IGF-1R (Igf1r+/−).
These APPsw and presenilin-1 ΔE9/Igf1r+/− mice showed
an increased assembly of Aβ into densely packed, ﬁbrillar
structures[139].Thisso-calledhyperaggregationsuggestsan
active aggregation of highly toxic Aβ oligomers to densely
packed aggregates which are less neurotoxic. In summary,
this study suggests that partial IGF-1 resistance protects the
brain from neurotoxicity mediated via Aβ oligomers [139].
In Caenorhabditis elegans, the knockdown of DAF-2, the
ortholog of mammalian IR and IGF-1R using siRNA (small
interference RNA) has been shown to reduce Aβ42 toxicity
[140]. This reduced toxicity was caused via the downstream
transcription factor DAF-16 (Abnormal dauer formation
16), the ortholog of the mammalian FoxO1 and FoxO3a,
and HSF-1 (heat shock transcription factor-1) [140–142].
HSF-1 induces disaggregation of the toxic Aβ oligomers and
degradation. In case this mechanism is oversaturated, DAF-
16 promotes the formation of hyperaggregated Aβ-peptides
which leads to aggregates with high-molecular weight and
less toxicity [140].
Recently, two mouse models expressing neuron-specif-
ically a dominant negative or constitutive active form of
FoxO1 (FoxO1DN and FoxO1ADA), have been published.
The ﬁrst mutant, FoxO1ADA, is nuclear expressed due to
mutation of T24 and S316 to A as well as a mutation of
S256 to D and acts constitutively active. The second FoxO1
mutant is transactivation domain deleted (FoxO1DN) and
exerts a dominant negative eﬀect. These mice were crossed
with Tg2576 mice and analyzed in respect to survival, APP
processing, and Aβ aggregation. FoxO1DN mice in a Tg2576
background showed no diﬀerences in survival up to 60
weeks of age compared to Tg2576 mice in both genders.
Interestingly, FoxO1ADA mice which mimic the situation
of an inactive IR/IGF-1R signaling pathway presented no
diﬀerences in Aβ burden. However, these mice showed an
increased mortality compared to Tg2576 mice for a yet
unknown reason [137]. Thus, in mammals FoxO1-mediated
transcription does not explain the beneﬁcial eﬀects mediated
via the IR/IGF-1 pathway.
An alternative downstream candidate of the IR/IGF-1R
signaling pathway is FoxO3a. Caloric restriction activates
the IR signaling pathway resulting in phosphorylation of
FoxO3a and nuclear exclusion [143]. A recent study showed
that this inactivation of FoxO3a leads to attenuation of
AD pathology and preservation of spatial memory in
Tg2576 mice. Accordingly, in vitro studies using primary
corticohippocampal Tg2567 neuron cultures expressing a
constitutive active FoxO3a revealed increased Aβ-peptide
production. In addition, FoxO3a is deacetylated by SIRT1
which might result in inhibition of FoxO3a-mediated tran-
scription during caloric restriction. This leads to reduced
Rho-associated protein kinase-1 (ROCK1) gene expression
followed by activation of the nonamyloidogenic processing
of APP and decreased levels of Aβ-peptides [143]. Thus,
animal experiments support the hypothesis that increased
FoxO-mediated transcription does not protect but rather
increase amyloid pathology.
The clearance of Aβ from the brain is facilitated via
diﬀerent mechanisms: (i) transport across the blood brain
barrier (BBB), (ii) phagocytosis by microglia, and (iii) enzy-
maticdegradation. TransportacrosstheBBBispromoted via
Aβ binding to the low-density lipoprotein receptor-related
protein (LRP) directly or via its associates to LRP in complex
with APOE (apolipoprotein E) and/or α2-macroglobulin
(α2M). After crossing the BBB Aβ-peptides are delivered to
peripheral tissues, for example, liver for degradation [144].
PreviousstudiesproposedthatIGF-1playsanimportantrole
for degradation and clearance of Aβ. This was supported by
the ﬁnding that Tg2576 mice have decreased IGF-1 levels
in comparison to wild-type animals and that the treatment
with IGF-1 causes an increased transport of Aβ out of the
brain [145]. Thus, there might be a diﬀerent role for IGF-
1R signaling in neurons and serum IGF-1 levels acting on Aβ
transport across the blood brain barrier. This point clearly
needs further investigations.
Taken together, studies in humans have shown neu-
ronal IR/IGF-1 resistance as being part of the patho-
genesis of AD. However, there seems to be a dual role
of IR/IGF-1 signaling in the pathogenesis of AD. Recent
animal experiments indicate that central insulin and IGF-
1 resistance is most likely a compensatory mechanism to
β amyloid pathology to reduce Aβ toxicity and promote
survival. But decreased IR/IGF-1 signaling causes tau hyper-
phosphorylation which is neurotoxic at least to certain
extend. Experiments in C. elegans suggested that FoxO
transcription factors might be involved in mediating the
beneﬁcial eﬀects of reduced IR/IGF-1R signaling. However,
studies in rodents favor that at least transgenically induced
increased FoxO-mediated transcription might be harmful
at least for AD pathology or AD-associated mortality,
favoring a concept for the exigency of optimal balanced
IR/IGF-1R → FoxO-mediated transcription under disease
conditions.
9.AlternativeTargetsRegulatedby
Insulin/IGF-1SignalingPossibly Involved
in Aging andPathogenesis of Dementia
However, FoxO-mediated transcription is not the only target
of the IR/IGF-1R signaling cascade. Alternative eﬀectors
downstream the IR/IGF-1R have been suggested as possibly
being involved in the pathogenesis of dementia or aging
itself.
ThePI3K pathwayleadstoactivation ofAKT.Inaddition
to phosphorylation of FoxO, it regulates tuberin 2 (TSC-
2). TSC-1 and -2 form a heterodimer harboring GTPase8 Current Gerontology and Geriatrics Research
activity and inhibiting the GTPase RHEB (RAS homolog
enriched in brain). Upon phosphorylation, the RHEB-GTP
complex accumulates and leads to activation of mTOR
(mammalian target of rapamycin) [146, 147]. Activated
mTOR phosphorylates 4E-BP (4E binding protein) which
then releases eIF4E (eukaryotic initiation factor 4E) pro-
moting translation initiation. Furthermore, activated PDK1
and mTOR activate the S6 kinase (S6K). S6K phosphorylates
eEF2 (eukaryotic elongation factor 2) kinase to release eEF2
which leads to initiation of elongation [148, 149]. Hence,
the IR/IGF-1R signaling cascade increases protein synthesis
in general. Recently, inhibition of mTOR using rapamycin
has been shown to increase lifespan and age-dependent
cognitive deﬁcits in mice [150, 151]. At the moment, no data
addressing the role of mTOR for the pathogenesis of AD are
available, but this will be an interesting direction for further
research.
The insulin/IGF-1 signaling cascade does not only reg-
ulate the PI3K pathway but also the MAP kinase (MAPK,
mitogen-activated protein kinase) cascade. After activation
of the insulin/IGF-1 signaling pathway, GRB-2 binds to
phosphorylated IRS proteins [36]. After that, GRB-2 recruits
son of sevenless (SOS), whichis a GDP/GTP exchangefactor.
Then the activation of the small G-protein RAS results
in association of c-raf leukemia viral oncogene (CRAF) to
the membrane activating kinase (MAPK). Finally, the MAP
kinases activate the extracellular signal-regulated kinase
(ERK-1/-2) [46]. The activity of ERK-1/-2 has been shown
to be involved in long-term potentiation and memory in
the CNS [47]. Thus, the MAP-kinase pathway might be
involved in certain aspects of the pathogenesis of dementia
as well.
10. Conclusion
Obesity in midlife and type 2 diabetes are associated with
an increased risk for vascular dementia and Alzheimer’s
disease. One common feature of obesity and type 2 diabetes
is hyperinsulinemia leading to insulin desensitization. This
has been identiﬁed at least as risk factor for cognitive decline.
At least in AD, neuronal IR/IGF-1R signaling is severely
impaired. Thus, reduced IR/IGF-1R signaling is part of the
pathogenesis of AD. Interestingly, deletion of the IGF-1R
in mouse models of AD leads to reduced mortality and
decreased Aβ load. Furthermore, haploinsuﬃciency for the
IGF-1R increased Aβ aggregation which is hypothesized to
be a molecular mechanism of detoxiﬁcation. Interestingly,
neuron-speciﬁc deletion of the IR reduced the Aβ burden
without inﬂuencing mortality. Thus, reduced IR/IGF-1R
signaling observed in AD brains might be a compensatory
mechanism protecting the brain against the toxic inﬂuence
of chronic elevated insulin levels. Data obtained from C.
elegans indicated that the FoxO transcription factors might
mediate the beneﬁcial eﬀect induced via decreased IR/IGF-
1 signaling. However, very recent data in rodents using
transgenic expression of diﬀerent FoxO variants nearly
excludes FoxO1-induced transcription as mediators for these
eﬀects.
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